Drug intelligence / Profile preview

interleukin-24 delE5

Development stage
Preclinical
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes
01

Overview

Interleukin-24 delE5 (IL-24 delE5) is a naturally occurring splice variant of the mda-7/IL-24 cytokine that lacks the sequence encoded by exon 5. While the full-length mda-7/IL-24 is primarily recognized for its ability to induce apoptosis in a wide range of cancer cells, IL-24 delE5 has been identified as a key regulator of monocytic differentiation in acute myeloid leukemia (AML). It functions by increasing the activity of NADPH oxidase, leading to the generation of reactive oxygen species (ROS), which subsequently triggers the differentiation of leukemic blasts into mature monocytes/macrophages. Research indicates that IL-24 delE5 is induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) through the MAPK/ERK signaling pathway and exhibits selective activity against malignant cells while sparing normal hematopoietic progenitors.

Other names
mda-7 delE5mda7 delE5mda 7 delE5interleukin-24 splice variant lacking exon 5interleukin24 splice variant lacking exon 5interleukin 24 splice variant lacking exon 5
02

Targets

IL-22R (Interleukin 22 Receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)IL20RA/IL20RB (Interleukin-20 Receptor)

Beyond the preview

Go deeper on interleukin-24 delE5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on interleukin-24 delE5.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call